公司資料
Genmab 股價、新聞與催化劑
- 股票代碼:
- GMAB
- 交易所:
- NASDAQ
- 產業:
- Antibody Drugs
- 所在地:
- Copenhagen, Denmark
股票表現
32.84 USD (+2.82%)
收盤價
最後更新: 2026年8月17日
14.6B USD
市值
股價為何變動
As of Aug 17, 2026, GMAB closed up 2.82% at $32.84. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Genmab is an antibody-focused biotechnology company with a long record of discovering and advancing differentiated cancer therapeutics. The company is known for its antibody engine, its partnered programs, and its ability to turn discovery into commercial or royalty-based value.
所在地與產業分類
Headquartered in Copenhagen, Denmark and listed on Nasdaq Copenhagen and as an ADR in the U.S., Genmab is a global biotechnology company. Its footprint spans Europe and the United States.
商業模式特徵
Genmab combines internal R&D with partnered programs, milestone revenue, and royalty income from successful antibodies. Investors follow clinical data, partner progress, and whether the company can keep producing validated antibodies from its discovery platform.
生技產業定位
Genmab sits in the premium end of antibody biotech because it has both scientific credibility and economic leverage from partnerships. The stock can move on data, deal flow, or royalty updates, making it a platform-driven catalyst name.
未來催化劑
- Genmab’s next three months are likely to focus on epcoritamab, combination data, and any label or expansion steps that deepen the antibody franchise. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。